Skip to main navigation Skip to search Skip to main content

Corrigendum to “A narrative review of approved and emerging anti-obesity medications” [Saudi Pharm. J. 31(10) (2023) 101757] (Saudi Pharmaceutical Journal (2023) 31(10), (S1319016423002529), (10.1016/j.jsps.2023.101757))

  • Dubai Pharmacy College
  • Gulf Medical University
  • University of Malaya
  • Najran University
  • Fourth-year pharmacy
  • Al Ain University of Science and Technology

Research output: Contribution to journal › Comment/debate

Abstract

The authors regret that Israa Yousif EL Khidir's university and email address was wrong in the published version. The correct details are as follows: Israa Yousif EL Khidir, Department of Clinical Pharmacy, (PhD, MSc), Assistant Professor, College of Pharmacy, Najran University, Najran -King Saudi Arabia (KSA). Email: [email protected], which has been corrected as above. The details listed in this corrigendum are correct and compl/ete. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Article number102047
JournalSaudi Pharmaceutical Journal
Volume32
Issue number5
DOIs
StatePublished - May 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Corrigendum to “A narrative review of approved and emerging anti-obesity medications” [Saudi Pharm. J. 31(10) (2023) 101757] (Saudi Pharmaceutical Journal (2023) 31(10), (S1319016423002529), (10.1016/j.jsps.2023.101757))'. Together they form a unique fingerprint.

Cite this